Journal of Pediatric Hematology/Oncology · 2009 · 92 citations · 18 references
MedicineHematologyOncologyChemotherapyImmunotherapyPediatric OncologyCancer ImmunotherapyCombination Cancer TherapyCombination ChemotherapyPediatric ChemotherapyPediatric LeukemiasRefractory Childhood CancerAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentB-cell Acute Lymphoblastic LeukemiaDose Escalation TherapyMaximum Tolerated EffectRefractory Acute Lymphoblastic LeukemiaRefractory LeukemiaRelapsed Acute Lymphoblastic Leukemia
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Combotox is a 1:1 mixture of RFB4-dgA and HD37-dgA which are immunotoxins that target the CD22 and CD19 antigens, respectively. Combotox has different toxicities and targets than chemotherapy and is, thus, a new candidate for the treatment of patients with relapsed ALL. Preclinical data have demonstrated which Combotox is effective in killing pre-B-ALL cell lines and cells from patients with pre-B ALL. METHODS: We designed and conducted a Phase 1 dose-escalation study using Combotox in children with refractory or relapsed B-lineage-ALL. Seventeen patients aged 1 to 16 years were enrolled in this multi-institution study. They were treated at 4-dose levels: 2 mg/m2, 4 mg/m2, 5 mg/m2, and 6 mg/m2. RESULTS: The maximum tolerated dose was 5 mg/m2 and graft versus host disease defined the maximum tolerated dose. Three patients experienced complete remission. Six additional patients experienced a decrease of >95% in their peripheral blood blast counts, and 1 patient experienced a decrease of 75%. CONCLUSIONS: Combotox can be safely administered to children with refractory leukemia. It has clinically important anticancer activity as a single agent. The recommended dose for future studies is 5 mg/m2/dose.
18
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Inhibitory Effects of B Cells on Antitumor Immunity
Satoshi Inoue, Wolfgang W. Leitner, Basil Golding et al. · Cancer Research · 2006 · 332 citations
Life Sciences, Immunology, Oncology +17
Phase I immunotoxin trial in patients with B-cell lymphoma.
E S Vitetta, Marvin J. Stone, P L Amlot et al. · PubMed · 1991 · 286 citations
Pharmacy, Hematology, Pharmacology +17